Insta
Australia Abandons Efforts To Develop Homegrown Covid-19 Vaccine After Volunteers In Trials Develop Antibodies For HIV
Swarajya Staff
Dec 14, 2020, 09:57 AM | Updated 09:57 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Australia has abandoned the development of homegrown Covid-19 vaccine candidate after numerous volunteers in the early-stage trials developed antibodies for HIV, as per media reports.
The Australian government had signed an agreement with Australian biotech company CSL Limited to supply 51m doses of a Covid-19 vaccine being developed by the University of Queensland.
The University of Queensland and CSL Limited said that their Covid-19 vaccine candidate would not progress to phase 2 and phase 3 clinical trials as researchers found the vaccine generated antibodies towards the “molecular clamp”, which led to a false positive result when participants were tested for HIV. A molecular clamp is a chain between proteins that stabilises the shape of proteins in experimental vaccines.
While the phase 1 study (involving 216 trial participants) found that the vaccine producing a strong immune response against Covid-19 and halted replication, some patients demonstrated antibodies towards fragments of an HIV protein (gp41). The researchers consulted the Australian Government. Following which they decided to not move ahead with phase 2 and 3 clinical trials.
The federal health minister, Greg Hunt, said public support of the vaccine and belief in its safety was essential. The news that the vaccine could trigger a HIV immune response may deter some people, even though it is a harmless response.
“The risk to vaccine confidence was the principal issue here, and we made the decision unanimously as a national security committee, the scientific advice was unanimous, the agreement with CSL not to proceed was mutual,” Hunt said.
The Australian government has invested more than A$3.3bn across the four vaccine agreements. This UQ/CSL vaccine was one of four candidates that Australia had committed to buy. The government is confident that the three other agreements (with AstraZeneca/University of Oxford, Novavax and Pfizer/BioNTech) will ensure that vaccination drives goes as per plan and schedule.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.